More in depth analysis in arriving on Opdivo and its impact on SIRT. The accelerated FDA approval immediately brings Opdivo to second line for HCC off crazy PhaseI-II data. Opdivo has a response rate of 15-20% versus sorafenib at 2%. PhaseIII reports next year and the oncology space is expecting a homerun which will bring it to first line.
People are expecting SIRT to be pushed back down the treatment waterfall and eventually they will have to start a new batch of clinical trials targeting SIRT +/vs Opdivo.
More in depth analysis in arriving on Opdivo and its impact on...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $61.98K | 351.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 11238850 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1266857 | 36 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |